Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. The company's core business revolves around being a leading global provider of high-quality, affordable medicines, primarily specializing in generic drugs, while also maintaining a significant portfolio of specialty medicines. Its mission is to improve global health by ensuring patient access and affordability of essential medicines worldwide.

Teva's extensive product portfolio includes a vast array of generic drugs, making it the world's largest generic medicines producer. Beyond generics, the company develops and markets branded pharmaceutical products such as Austedo (for Huntington's disease and tardive dyskinesia), Ajovy (for migraine prevention), Copaxone (for multiple sclerosis), Bendeka and Treanda (for oncology), and Uzedy (for schizophrenia). Teva also produces active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products. The company focuses its innovative efforts across key therapeutic areas including Central Nervous System (CNS), respiratory, oncology, and immunology, serving patients in over 60 countries with a strong presence in North America and Europe.

Under the leadership of President and CEO Richard Francis and Chairman Sol Barer, Teva is currently executing a "Pivot to Growth" strategy, emphasizing high-value specialty medicines and complex generics to drive future expansion and improve profitability. Recent notable developments include strong first-quarter 2026 results, largely driven by its innovative medicine portfolio. In April 2026, Teva announced an agreement to acquire Emalex Biosciences, adding Ecopipam, an investigational treatment for pediatric Tourette syndrome, to its neuroscience pipeline, with the transaction expected to close by Q3 2026. The company has also expressed confidence in its plans to boost operating profit margins to 30% by 2027.